Thymalfasin is synthetic thymosin alpha-1: a defined 28-amino-acid peptide with an N-terminal acetyl group. Sequence and acetylation are part of identity, not optional catalog details.
Evidence at a glance
- PubChem lists thymalfasin as a 28-residue peptide with molecular weight 3108.3 g/mol.
- Its recorded sequence is Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN-OH.
- Immunologic mechanism language does not override the neutral 2025 phase 3 sepsis result.
Identity record
An unacetylated 28-mer and N-acetylated thymalfasin differ by a defined chemical modification. The certificate and mass acceptance criteria should match the actual terminal state.
Analytical and evidence boundary
Peptide purity by a single UV chromatogram is incomplete. Orthogonal identity, quantitative peptide content and related-substance characterization are especially useful for a long, acidic sequence.
Use “studied as an immunomodulator” for literature context. Avoid claiming mortality benefit in sepsis, because the largest modern trial found no clear evidence for that outcome.
Editorial rule
State the exact material, form, model or population and endpoint supported by the cited record. Do not convert mechanistic plausibility, an animal result, a finished-drug label or an analytical test into a claim about an unrelated catalog lot.
Sources & editorial method
The editorial workflow began with linked PubMed primary papers, systematic reviews, PubChem identity records and FDA/DailyMed regulatory records. Population or model, denominators, endpoints, numerical results, null findings, limitations and conflicts were extracted before drafting. AI-assisted drafting and original image generation were used; the final facts and evidence boundaries were checked against the linked records on 2026-09-02. This is not independent peer review.
3 linked records are listed in the references below. Read the editorial and AI-assistance policy.
How to interpret this article
Source-checked on 2026-09-02. Null results, study size, model/population limits and relevant conflicts are retained. This is not medical advice, a customer case or validation of a catalog lot.
Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.
Primary records and authoritative sources
- TESTS phase 3 thymosin alpha-1 sepsis trialPrimary 2025 multicenter trial; PMID 39814420.
- 2025 thymosin alpha-1 sepsis meta-analysisEleven RCTs with quality and trial-sequential analyses; PMID 40969554.
- PubChem Thymalfasin recordSequence, formula, mass and synonym record; CID 16130571.
Continue with structured records
Move from this editorial analysis to the product identity, filtered evidence and controlled terminology behind it.
